171 related articles for article (PubMed ID: 28706179)
21. Adherence to treatment with second-line therapies, dasatinib and nilotinib, in patients with chronic myeloid leukemia.
Yood MU; Oliveria SA; Cziraky M; Hirji I; Hamdan M; Davis C
Curr Med Res Opin; 2012 Feb; 28(2):213-9. PubMed ID: 22168217
[TBL] [Abstract][Full Text] [Related]
22. Tyrosine kinase inhibitor therapy prescribed for non-urologic diseases can modify PSA titers in urology patients.
Sasaki T; Franco OE; Ohishi K; Filipovich Y; Ishii K; Crawford SE; Takahashi N; Katayama N; Sugimura Y; Hayward SW
Prostate; 2019 Feb; 79(3):259-264. PubMed ID: 30370673
[TBL] [Abstract][Full Text] [Related]
23. [Chronic myeloid leukemia].
Usui N
Nihon Rinsho; 2014 Jun; 72(6):1068-72. PubMed ID: 25016806
[TBL] [Abstract][Full Text] [Related]
24. Long-term outcomes in the second-line treatment of chronic myeloid leukemia: a review of tyrosine kinase inhibitors.
Jabbour E; Cortes J; Kantarjian H
Cancer; 2011 Mar; 117(5):897-906. PubMed ID: 20945321
[TBL] [Abstract][Full Text] [Related]
25. Relationship between trough level of tyrosine kinase inhibitor (imatinib and nilotinib) and BCR-ABL ratios in an Indonesian chronic-phase chronic myeloid leukemia (CML) population.
Suprapti B; Andarsari MR; Hapsari PP; Khotib J; ; Bintoro SUY
J Basic Clin Physiol Pharmacol; 2020 Aug; 31(5):. PubMed ID: 32764164
[TBL] [Abstract][Full Text] [Related]
26. [State-of-the-art management of CML in 2015 and future prospects].
Kimura S
Rinsho Ketsueki; 2015 Oct; 56(10):2005-14. PubMed ID: 26458439
[TBL] [Abstract][Full Text] [Related]
27. Discovery and Protein Modeling Studies of Novel Compound Mutations Causing Resistance to Multiple Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia.
Iqbal Z; Absar M; Mahmood A; Aleem A; Iqbal M; Jameel A; Akhtar T; Karim S; Rasool M; Mirza Z; Khalid M; Akram AM; Sabar MF; Khalid AM; Aljarrah K; Iqbal J; Khalid M; Shah IH; Alanazi N
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3517-3526. PubMed ID: 33369447
[TBL] [Abstract][Full Text] [Related]
28. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.
Kantarjian HM; Hochhaus A; Saglio G; De Souza C; Flinn IW; Stenke L; Goh YT; Rosti G; Nakamae H; Gallagher NJ; Hoenekopp A; Blakesley RE; Larson RA; Hughes TP
Lancet Oncol; 2011 Sep; 12(9):841-51. PubMed ID: 21856226
[TBL] [Abstract][Full Text] [Related]
29. Adverse events associated with nilotinib in chronic myeloid leukemia: mechanisms and management strategies.
Wang Z; Jiang L; Yan H; Xu Z; Luo P
Expert Rev Clin Pharmacol; 2021 Apr; 14(4):445-456. PubMed ID: 33618586
[No Abstract] [Full Text] [Related]
30. Treatment patterns, overall survival, healthcare resource use and costs in elderly Medicare beneficiaries with chronic myeloid leukemia using second-generation tyrosine kinase inhibitors as second-line therapy.
Smith BD; Liu J; Latremouille-Viau D; Guerin A; Fernandez D; Chen L
Curr Med Res Opin; 2016 May; 32(5):817-27. PubMed ID: 26743563
[TBL] [Abstract][Full Text] [Related]
31. Nilotinib as frontline and second-line therapy in chronic myeloid leukemia: open questions.
Valent P; Gastl G; Geissler K; Greil R; Hantschel O; Lang A; Linkesch W; Lion T; Petzer AL; Pittermann E; Pleyer L; Thaler J; Wolf D
Crit Rev Oncol Hematol; 2012 Jun; 82(3):370-7. PubMed ID: 21903413
[TBL] [Abstract][Full Text] [Related]
32. Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results.
le Coutre PD; Giles FJ; Hochhaus A; Apperley JF; Ossenkoppele GJ; Blakesley R; Shou Y; Gallagher NJ; Baccarani M; Cortes J; Kantarjian HM
Leukemia; 2012 Jun; 26(6):1189-94. PubMed ID: 22076466
[TBL] [Abstract][Full Text] [Related]
33. Important therapeutic targets in chronic myelogenous leukemia.
Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
[TBL] [Abstract][Full Text] [Related]
34. Tyrosine kinase inhibitor nilotinib induced palmoplantar erythrodysesthesia: A rare case.
Aslaner Ak M; Ertop Doğan P; Sahip B
J Oncol Pharm Pract; 2022 Apr; 28(3):763-765. PubMed ID: 35465793
[TBL] [Abstract][Full Text] [Related]
35. Sequential use of second-generation tyrosine kinase inhibitors following imatinib therapy in pediatric chronic myeloid leukemia: A report from the Japanese Pediatric Leukemia/Lymphoma Study Group.
Kurosawa H; Tanizawa A; Muramatsu H; Tono C; Watanabe A; Shima H; Ito M; Yuza Y; Hamamoto K; Hotta N; Okada M; Saito AM; Manabe A; Mizutani S; Adachi S; Horibe K; Ishii E; Shimada H
Pediatr Blood Cancer; 2018 Dec; 65(12):e27368. PubMed ID: 30084127
[TBL] [Abstract][Full Text] [Related]
36. Effects of first- and second-generation tyrosine kinase inhibitor therapy on glucose and lipid metabolism in chronic myeloid leukemia patients: a real clinical problem?
Iurlo A; Orsi E; Cattaneo D; Resi V; Bucelli C; Orofino N; Sciumè M; Elena C; Grancini V; Consonni D; Orlandi EM; Cortelezzi A
Oncotarget; 2015 Oct; 6(32):33944-51. PubMed ID: 26376678
[TBL] [Abstract][Full Text] [Related]
37. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
[TBL] [Abstract][Full Text] [Related]
38. Physician's guide to the clinical management of adverse events on nilotinib therapy for the treatment of CML.
Rosti G; Castagnetti F; Gugliotta G; Palandri F; Baccarani M
Cancer Treat Rev; 2012 May; 38(3):241-8. PubMed ID: 21840128
[TBL] [Abstract][Full Text] [Related]
39. Nilotinib therapy in chronic myelogenous leukemia.
Quintas-Cardama A; Cortes J
Drugs Today (Barc); 2007 Oct; 43(10):691-702. PubMed ID: 17987222
[TBL] [Abstract][Full Text] [Related]
40. Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML.
Aichberger KJ; Herndlhofer S; Schernthaner GH; Schillinger M; Mitterbauer-Hohendanner G; Sillaber C; Valent P
Am J Hematol; 2011 Jul; 86(7):533-9. PubMed ID: 21538470
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
